About the Authors
- Iryna Dekhtiarenko
-
Contributed equally to this work with: Iryna Dekhtiarenko, Robert B. Ratts
Affiliation Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany
- Robert B. Ratts
-
Contributed equally to this work with: Iryna Dekhtiarenko, Robert B. Ratts
Affiliation TomegaVax Inc., Portland, Oregon, United States of America
- Renata Blatnik
-
Affiliations Immunotherapy and prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany, Molecular Vaccine Design, German Center for Infection Research (DZIF), Heidelberg, Germany
- Lian N. Lee
-
Affiliation Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Sonja Fischer
-
Affiliation Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany
- Lisa Borkner
-
Affiliation Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany
- Jennifer D. Oduro
-
Affiliation Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany
- Thomas F. Marandu
-
Affiliations Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany, Dar es Salaam University College of Education, Dar es Salaam, Tanzania
- Stephanie Hoppe
-
Affiliations Immunotherapy and prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany, Molecular Vaccine Design, German Center for Infection Research (DZIF), Heidelberg, Germany
- Zsolt Ruzsics
-
Affiliation Institute for Virology, University Medical Center Freiburg, Freiburg, Germany
- Julia K. Sonnemann
-
Affiliation Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany
- Mandana Mansouri
-
Affiliation Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America
- Christine Meyer
-
Affiliation TomegaVax Inc., Portland, Oregon, United States of America
- Niels A. W. Lemmermann
-
Affiliation Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
- Rafaela Holtappels
-
Affiliation Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
- Ramon Arens
-
Affiliation Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands
- Paul Klenerman
-
Affiliation Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Klaus Früh
-
Affiliations TomegaVax Inc., Portland, Oregon, United States of America, Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America
- Matthias J. Reddehase
-
Affiliation Institute for Virology and Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
- Angelika B. Riemer
-
Affiliations Immunotherapy and prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany, Molecular Vaccine Design, German Center for Infection Research (DZIF), Heidelberg, Germany
- Luka Cicin-Sain
-
* E-mail: luka.cicin-sain@helmholtz-hzi.de
Affiliations Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany, German Center for Infection Research (DZIF), Partner site Hannover/Braunschweig, Germany, Institute for Virology, Medical School Hannover, Germany
Competing Interests
The authors declare the following competing financial interest: Oregon Health and Science University (OHSU) and KF have a significant financial interest in TomegaVax Inc., a company that may have a commercial interest in the results of this research and technology. LCS was a paid consultant of Tomegavax in 2015. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU. RBR and CM have been employed by TomegaVax, Inc., a commercial company. The authors declare that there are no further financial interests.
Author Contributions
Conceptualization: ID RA PK KF MJR ABR LCS. Formal analysis: ID LCS. Funding acquisition: ABR LCS. Investigation: ID RBR RB LNL SF LB JDO TFM SH JKS. Methodology: ID RBR RB LNL ZR MM CM NAWL RH. Project administration: LCS. Resources: ZR. Supervision: PK KF ABR. Visualization: ID RBR LNL RB. Writing – original draft: ID LCS. Writing – review & editing: RBR RA PK KF MJR ABR LCS.